BRKRP earnings call summary

Prepared Highlights

• Q1 2026 reported revenue $823.4M, +2.7% YoY (FX tailwind +4.5%, M&A +2.6%, organic –4.4%) (CFO)
• BSI segment organic bookings grew high-single-digits YoY; BSI book-to-bill >1.0x for third consecutive quarter (CEO)
• BSI segment organic revenue –5% YoY; BEST segment organic revenue +3% YoY (CEO)
• Non-GAAP gross margin 50.0% (–130 bps YoY); non-GAAP operating margin 10.2% (–250 bps YoY); headwinds from lower volume/mix (–350 bps), FX (–170 bps), tariffs (–30 bps), partly offset by cost savings (+300 bps) (CFO)
• Non-GAAP diluted EPS $0.31 (vs $0.47 in Q1 2025), includes $0.05 FX headwind and $0.05 impact from MCP offering (CFO)
• Operating cash flow $71M; CapEx $24M; free cash flow $47M, +$8M YoY (CFO)
• Ended Q1 with cash ~$133M; debt paydown $180M; net leverage ratio 2.9x (CFO)
• AI-driven Semi Metrology (>$300M annual revenue) organic bookings >20% growth; SciY software ($50M revenue) and security detection ($70M revenue expected this year) also >20% organic bookings growth (CEO)
• BEST segment received ~$80M multi-year orders for Fusion Technologies (Q1) and ~$600M multi-year orders for superconductors from MRI customers (Dec–Apr) (CEO)
• CALID Group revenue $316M, mid-single-digit CER growth; BioSpin $198M, high-single-digit CER decline; Bruker Nano $246M, mid-single-digit CER decline (CEO)
• Q1 organic revenue by end-market: semi, biopharma, hospital clinical grew; Academic & Government research and industrial declined double-digits (CFO)
• Cost-saving plan tracking ~$140M annualized (up from prior $100–120M target); majority expected in H2 2026 (CFO)

Official Guidance (FY 2026)

• Reported revenue: $3.57B – $3.60B (+4% to +5% YoY)
• Organic revenue growth: +1% to +2% YoY; M&A +1.5%; FX tailwind +1.5%
• Non-GAAP operating margin expansion: +250 to +300 bps (from 12.6% in FY 2025); organic expansion +300 to +350 bps, offset by ~50 bps FX headwind
• Non-GAAP EPS: $2.10 – $2.15 (+15% to +17% YoY); CER EPS growth +23% to +25%
• Q2 2026 organic revenue growth expected: low- to mid-single-digit YoY; meaningful YoY step-up in non-GAAP operating margin and EPS (CFO)

Mgmt Quotes

• "Our first quarter '26 financial performance came in well ahead of expectations." (CEO)
• "Order strength in Semi Metrology... was driven by AI demand for memory chips and for advanced packaging." (CEO)
• "We are very committed to controlling and reducing costs, which is crucial to improving our margin profile rapidly." (CEO)
• "We delivered financial performance ahead of expectations we outlined in our earnings call in February." (CFO)
• "The highlight of the quarter was our strong bookings performance, with BSI segment organic bookings up high-single-digits." (CFO)

Q&A Batch (1-5 of 6)

Q1 — Frank Laukien (Michael Ryskin & Puneet Souda)

• Topic: 海外需求趋势、安全/国防业务及利润率下半年回升
• Key points:
  • Q1海外ACA/GOV订单增速较高，但“probably not sustainable”（不可持续），预期高个位数增长。
  • 安全/国防业务增速约20%，合计占收入“well above 10%”, 估测>12%，可抵消部分美国学术市场疲弱。
  • 全年运营利润率改善300-350 bps，下半年更强，受成本节约与市场条件改善驱动。
• Mgmt stance: 中性偏乐观：海外需求健康，但不可线性外推；Q1运利润因成本行动已体现，下半年更佳。

Q2 — Tycho Peterson (Frank Laukien & Gerald Herman)

• Topic: 半导体业务推回、美国学术复苏与Q2营收指引
• Key points:
  • 上季度半导体推后$40M，Q1仅部分收回（“some, but not all”）；全年半导体仍维持低个位数增长预期（团队点头确认）。
  • 美国学术订单已见底或稳定（“bottomed or stabilized”），但未计入2026年指引，若释放资金可形成Q2/Q3订单，对营收属“upside”。
  • Q2运营利润率“significant pickup”，B2B保持>1；营收预期低至中等个位数有机增长（未给出具体数字）。
• Mgmt stance: 中性偏谨慎：半导体恢复有限；美国学术预期改善但未纳入指引；Q2利润率有提升但无明确数值。

Q3 — Brandon Couillard (Gerald Herman & Frank Laukien)

• Topic: 中国营收下降、订单改善与BioSpin领导层变动
• Key points:
  • 中国Q1营收同比下降超20%，主要受上年弱势订单传导；但Q1订单“solid”（坚实），尽管基数偏弱。
  • 中国诊断业务（主要聚焦欧洲/美国/其他地区）几乎无中国直接敞口，未受外部冲击。
  • BioSpin前领导Falko Busse已离职，目前过渡期；Frank将于7月中公布新集团架构，强调客户导向与成本效率。
• Mgmt stance: 中性：中国营收下滑是滞后效应，订单略有回暖；对BioSpin重组持积极态度。

Q4 — Douglas Schenkel (Frank Laukien & Gerald Herman)

• Topic: Q2增长是否为全年最高、成本及关税影响、年初至今不调指引
• Key points:
  • Q1可能有$8M-$10M收入从Q2拉前，不显著；Q2有机增速为全年最强（因基数较低）。
  • 已计入2026增收的250-300 bps利润率改善，涵盖中等运费、氦气、能源成本上升；未因Q1上修指引，保持原目标。
  • 成本节约计划（年化约$140M）已预留缓冲，以应对通胀与不确定性。
• Mgmt stance: 中性偏防御：依靠成本把控确保利润率目标，主动保留指引不变以增强置信度。

Q5 — Subhalaxmi Nambi (Frank Laukien & Gerald Herman)

• Topic: 终端市场假设、国防尾流、利润率组合与BEST订单
• Key points:
  • 第二季度海外ACA/GOV、工业、半导体持续强劲；临床微生物学与分子诊断放置量Q1超计划40%（利好后续耗材）。
  • 中东冲突对国防检测业务已有支持（过去2-3年规模翻倍），但大单交付周期长，不影响2026年指引，潜在影响延伸至2027-2028。
  • Q1运利润组合“un

Q&A Batch (6-6 of 6)

Q6 — Patrick Donnelly

• Topic: 欧洲ACA/GOV业务展望及Q2业绩指引
• Key points:
  • 欧洲Q1表现良好，但管理层预计未来为中等至高位个位数有机增长（未指定低/中/高），因存在季度波动。
  • 推动因素包括：欧洲研究预算增加（部分受国防支出拉动）、蛋白质组学2.0（完整功能蛋白）设备需求、空间生物学技术领导地位、以及NMR复苏。
  • Q2 2026不预期有千兆赫级系统交付，这将影响模型预测。
  • Q2营业利润率预计环比Q1显著提升，同比亦改善；Q2每股收益预计环比Q1更好。
• Mgmt stance: 中性偏乐观——欧洲增长预期明确（中高个位数），但强调季度波动；Q2利润率与EPS环比改善，但无具体数字。